Evaluation of quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy
DOI:
https://doi.org/10.33448/rsd-v10i11.19775Keywords:
Monoclonal antibody; Atopy; Canine; IL-31; Questionnaire.Abstract
Canine atopic dermatitis is an inflammatory and pruritic skin disease, with clinical characteristics associated with IgE antibodies, most commonly directed against environmental allergens which impact the quality of life in affected animals and their owners. Treatment is multifaceted and must be adapted to each patient individually. Currently, a medication based on caninized monoclonal antibody (mAb), called lokivetmab, has shown promise for controlling the signs of the disease, as it neutralizes interleukin IL-31, a cytokine that plays an important role in the pathogenesis of atopy. The impact of dermatological diseases in the life of the dog and its owner has only been studied in recent years through validated questionnaires. This additional measurement tool is important for evaluating the therapeutic success of interventions in atopic dermatitis, as clinical improvement may not correlate with an increased quality of life. This study aimed to evaluate the quality of life in dogs with atopic dermatitis and their owners after lokivetmab therapy. Ten atopic dogs treated at the dermatology service of the Veterinary Hospital of the Veterinary School from UFMG were selected. Quality of life was assessed using a validated questionnaire, before and after lokivetmab therapy. It concludes that treatment with lokivetmab significantly improved the quality of life of dogs with atopic dermatitis and their owners.
References
Balkrishnan, R., Housman, T. S., Carroll, C., Feldman, S. R., & Fleischer, A. B. (2003). Disease severity and associated family impact in childhood atopic dermatitis. Archives of Disease in Childhood, 88(5), 423-427.
Bruet, V., Bourdeau, P., Roussel, A., Imparato, L., & Desfontis, J. C. (2012). Characterization of pruritus in canine atopic dermatitis, flea bite hypersensitivity and flea infestation and its role in diagnosis. Vet Dermatol, 23(6), 487-493.
Chamlin, S. L., Lai, J. S., Cella, D., Frieden, I. J., Williams, M .L., Mancini, A. J., & Chren, M. M. (2007). Childhood atopic dermatitis impact scale: reliability, discriminative and concurrent validity, and responsiveness. Archives of Dematology, 143(6), 768-772.
Cosgrove, S. B., Cleaver, D. M., King, V. L, Gilmer, A. R., Daniels, A. E., Wren, J. A., & Stegemann, M .R. (2015). Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol, 26(3), 171-179.
Favrot, C., Steffan, J., Seewald, W., & Picco, F. (2010a). A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Vet Dermatol, 21(1), 23–31.
Favrot, C., Linek, M., Mueller, R., & Zini, E. (2010b). Development of a questionnaire to assess the impact of atopic dermatitis on health-related quality of life of affected dogs and their owners. Vet Dermatol, 21(1), 63-69.
Griffin, C. E., & Deboer, D. J. (2001). The ACVD task force on canine atopic dermatitis (XIV): clinical manifestations of canine atopic dermatitis. Vet Immunol Immunopathol, 81(3-4), 255-269.
Halliwell, R. (2006). Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol, 114 (3–4), 207–208.
Jackson, H., & Forsythe, P. (2020). New therapies for canine atopic dermatites. Clin Pract, 42(2), 82-90.
Linek, M., & Favrot, C. (2010). Impact of canine atopic dermatitis on the health-related quality of life of affected dogs and quality of life of their owners. Vet Dermatol, 21(5), 456-462.
Marsella, R., & De Benedetto A. (2017). Atopic Dermatitis in Animals and People: An Update and Comparative Review. Vet Sci, 4(3), 1-19.
Medeiros, V.B. (2017). Canine atopic dermatitis. J Surg Cl Res, 8(1), 106-117.
Moyaert, H., Van Brussel, L., Borowski, S., Escalada, M., Mahabir, S. P., Walters, R. R., & Stegemann, M. R. (2017). A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client owned dogs with atopic dermatitis. Vet Dermatol, 28(6), 593–e145.
Noli, C., Minafò, G., & Galzerano, M. (2011a). Quality of life of dogs with skin disease and their owners - part 1: development and validation of a questionnaire. Vet Dermatol, 22(4), 335-343.
Noli, C., Colombo, S., Cornegliani, L., Ghibaudo, G., Persico, P., Vercelli, A., & Galzerano, M. (2011b). Quality of life of dogs with skin disease and of their owners - part 2: administration of a questionnaire in various skin diseases and correlation to efficacy of therapy. Vet Dermatol, 22(4), 344-351.
Nguyen, T. S., Simpson, B., L’estrange, R. et al. (2018). Progress report from an early experience program involving atopic dogs treated with lokivetmab reaching 30 days post injection using a mobile application monitoring pruritus and dog and owner quality of life (QoL) [Resumo]. In Australian Vet Association Annual Conference Brisbane. Queensland. Anais: Proceedings from the Australian Small Animal Veterinarians Innovation, Research and Development Symposium (p. 9–10). Queensland, Austrália.
Noli, C., Della Valle, M .F., Miolo, A., Medori C., & Schievano, C. (2015). Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study. Vet Dermatol, 26(6), 432-440.
Noli, C., Borio, S., Varina, A., & Schievano, C. (2016). Development and validation of a questionnaire to evaluate the quality of life of cats with skin disease and their owners and its use in 185 cats with skin disease. Vet Dermatol, 27(4), 247-e58.
Noli, C., Sartori, R., Cena, T. (2017). Impact of a terbinafine–florfenicol–betamethasone acetate otic gel on the quality of life of dogs with acute otitis externa and their owners. Vet Dermatol, 28(4), 386-e90.
Olivry, T., Saridomichelakis, M., Nuttall, T., Bensignor, E., Griffin, C.E., & Hill, P. B. (2014). Validation of the Canine Atopic 20 Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs. Vet Dermatol, 25(2), 77-86.
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da Pesquisa Científica. Retrieved from https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1
Souza, C. P., Rosychuk, R. A. W., Contreras, E. T., Schissler, J.R., & Simpson, A.C. (2018). A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Vet Dermatol, 9(5), 489-e164.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Vanessa Stuart Marques; Jessica Ragazzi Celesso; Adriane Pimenta da Costa Val Bicalho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
